Fennec Pharmaceuticals Inc. (FRX.TO)
| Previous Close | 13.62 |
| Open | 13.13 |
| Bid | 13.26 x 0 |
| Ask | 13.44 x 0 |
| Day's Range | 13.13 - 13.13 |
| 52 Week Range | 5.94 - 14.41 |
| Volume | |
| Avg. Volume | 916 |
| Market Cap | 344.802M |
| Beta (5Y Monthly) | 0.07 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Baystreet
Stocks in play: Fennec Pharmaceuticals Inc
Announced that the U.S. Food and Drug Administration has granted Orphan Drug Exclusivity to PEDMARK® ...
- GlobeNewswire
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA
~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK® from its FDA Approval on September 20, 2022 Until September 20, 2029 ~ ~ Additionally, the Company Has Three FDA Orange Book Listings Providing U.S. Patent Protection for PEDMARK® Until 2039 ~ RESEARCH TRIANGLE PARK, N.C., Jan
- GlobeNewswire
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Percent or Higher,1 Underscoring Need to Mitigate the Profound Impact Hearing Loss Can Have on a Child’s Learning and Development ~ RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals
